We will include eligible participants: 1 diagnosed with NAFLD; 2 aged 18 to 65 years; 3 with imaging evidence of liver MRI-PDFF ≥ 5%; 4 BMI < 35 kg/m2; 5 willing to follow the scheduled visit plan; 6 with serum alanine aminotransferase (ALT) < 5 times the upper normal limit (ULN); and 7 and signed informed consent. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.